Step-by-step guides, research summaries, and treatment overviews β reviewed by oncology navigators and written clearly for patients, families, and caregivers.
From newly diagnosed to relapsed and refractory β we publish what patients actually need to understand their options.
What are you looking for today?
CancerFax Insights exists because cancer patients face decisions that are genuinely hard β not because of lack of will, but because the information landscape is fragmented, fast-moving, and often written for clinicians, not families.
Every insight published here is reviewed by our oncology navigation team before it goes live. We focus on the questions patients actually ask us: What is this treatment? Who qualifies? What should I prepare? What should I ask my doctor?
Use the search and filters below to find what's most relevant to your situation.
Step-by-step patient guide
Before agreeing to CAR-T therapy, families need to understand eligibility criteria, the manufacturing timeline, expected side effects, and what happens if the therapy fails. This guide walks through every question your team should be able to answer.
Browse by the topic most relevant to where you are in your cancer journey right now.
Compare options, evaluate trade-offs, understand what questions to ask before agreeing to a specific protocol.
How trial matching works, eligibility logic explained, document checklists, and what to expect during screening.
NGS testing, biomarker-based treatment matching, liquid biopsy, tumour mutation burden, and targeted therapy guides.
Cross-border treatment pathways, China and India access, visa planning, cost estimates, and logistics walk-throughs.
Practical guides for families, partners, and adult children walking alongside someone in cancer treatment.
How to prepare records, frame clinical questions, compare opinions, and navigate specialist review across borders.
Search, filter, and explore all published insights β by cancer type, treatment category, clinical trial readiness, or stage of your journey.
Search across cancer types, treatments, mutations, drugs, and trials
Hormone Therapy
CancerFax helps patients access hormone therapy drugs and specialist oncology management in India and China β combining drug cost savings of 90β98% with quality-verified supply chains, prescribing coordination, and ongoing monitoring support for patients in any country.
Hormone Therapy
Enzalutamide, abiraterone, and darolutamide are three approved next-generation hormonal agents that have transformed prostate cancer outcomes β used alongside ADT in both hormone-sensitive and castration-resistant disease. They differ in mechanism, blood-brain barrier penetration, steroid co-prescription requirement, and drug interaction profiles.
TACE
Zhongshan Hospital affiliated with Fudan University in Shanghai is one of Asia's highest-volume liver cancer centres β performing over 1,000 TACE procedures annually and housing the internationally recognised Liver Cancer Institute that pioneered China's surgical and interventional hepatology programmes. It is a primary destination for international HCC patients seeking TACE in China.
CancerFax Services
Precision oncology uses biomarker testing β including IHC, FISH, NGS, and liquid biopsy β to match cancer patients with treatments that target the specific molecular drivers of their tumour, rather than treating all cancers of the same organ type identically. Getting the right biomarker panel at the right time is now one of the most consequential decisions in cancer care.
TARE / Y-90 Radioembolization
China's two leading Y-90 radioembolization centres for liver cancer are Zhongshan Hospital (Fudan University, Shanghai) β one of Asia's highest-volume hepatobiliary centres β and Eastern Hepatobiliary Surgery Hospital (EHBH, Shanghai) β the world's largest specialist liver surgery and liver cancer institution. Both offer TheraSphere and SIR-Spheres with personalised dosimetry and dedicated international patient programmes, accessible via CancerFax.
Cancer Surgery
China's leading academic cancer centres β PUMCH, Zhongshan, Fudan, and Sun Yat-sen University Cancer Centre β perform the world's highest volumes of hepatic resection, gastrectomy, and colorectal cancer surgery, with outcomes comparable to leading Western institutions. Cancer surgery costs in China are 60β75% lower than in the USA, with robotic and minimally invasive surgery widely available. International patient departments at major centres provide English-language support and structured access for overseas patients.
Cancer Surgery
Cancer surgery costs vary enormously by country. India offers the greatest cost savings β 70β85% less than the USA for equivalent procedures β with equivalent surgical technology and internationally trained oncological surgeons. China offers similar savings with the world's highest volumes for gastric and liver cancer surgery. Israel and Thailand provide intermediate cost profiles with strong English-language environments. Total costs including travel are still typically 50β70% less than in the USA or UK even with international access.
Interventional Oncology
Multiple randomised controlled trials comparing RFA to hepatic resection for small HCC (β€3 cm, BCLC stage 0/A) show equivalent overall survival β the landmark finding that placed ablation alongside surgery in BCLC and EASL guidelines. The key differences: surgery has higher complication rates and mortality; RFA has higher local recurrence rates (but retreatment with repeat RFA is effective). For cirrhotic patients with small single HCC, BCLC guidelines recommend both as first-line curative options, with the choice depending on tumour location, liver function, and patient preference.
Interventional Oncology
China has the world's highest hepatocellular carcinoma burden β approximately 50% of global HCC cases β driving the development of liver RFA expertise that is unmatched anywhere. Zhongshan Hospital (Fudan University, Shanghai) and the Eastern Hepatobiliary Surgery Hospital (EHBH, Shanghai) are China's two most internationally recognised liver cancer centres, each performing thousands of liver ablation procedures annually. For international patients, China offers world-class liver RFA at costs 4β8Γ lower than comparable Western centres.
Where are you in your cancer journey? Find insights matched to your current situation.
Understand your diagnosis, staging, reports, and first-line options before making major decisions.
Read newly-diagnosed insightsExplore second opinions, molecular testing, clinical trials, and international advanced options.
Explore next-step insightsLearn how trial matching, eligibility review, and mutation-based screening actually work.
View clinical trial insightsUnderstand how destination, treatment availability, cost, and expertise shape cross-border decisions.
Compare destinationsCurated reading lists for patients going deep into a specific treatment category or clinical question.
Cell & gene therapy
Precision oncology
Advanced radiation & local therapies
Explore insights and guides organised by the treatment modality most relevant to your case.
Find content specific to your diagnosis β from treatment overviews to clinical trial access and second opinion guidance.
Clinical trial access
CancerFax connects patients with clinical trials in China, India, and leading global centres β including phase I and II trials closed to international enrolment through standard channels.
500+
active clinical trials across China, India, and leading global centres
40+
cancer types with current advanced therapy access pathways
12+
years of patient navigation experience in cross-border oncology
Insights our navigation team recommends most often to patients starting their research.
Treatment guide Β· 8 min
02Second opinion Β· 6 min
03Precision oncology Β· 10 min
04Clinical trials Β· 7 min
05Clinical trials Β· 9 min
06Precision oncology Β· 5 min
A note from the CancerFax team
CancerFax Insights is editorially independent of the hospitals, pharmaceutical companies, and treatment centres we work with. Our navigation team writes what patients need to hear β not what any institution wants them to read.
That means we tell patients when a treatment is likely out of reach, when a clinical trial has closed, and when the evidence for a new therapy is still thin. We believe informed patients make better decisions and have better outcomes β even when the honest answer is harder to hear.
β CancerFax oncology navigation team
How our content is produced, reviewed, and how to use it effectively.
Our oncology navigators review your medical records, explain your options in plain language, and help you access the right specialists, trials, and treatment centres β wherever you are in the world.
Every navigation request is reviewed by a qualified oncology professional. We do not recommend treatments without reviewing your medical records.
